Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
Journal Article (Journal Article)
Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number NCT01835158.
Full Text
Duke Authors
Cited Authors
- George, DJ; Hessel, C; Halabi, S; Michaelson, MD; Hahn, O; Walsh, M; Picus, J; Small, EJ; Dakhil, S; Feldman, DR; Mangeshkar, M; Scheffold, C; Morris, MJ; Choueiri, TK
Published Date
- November 2019
Published In
Volume / Issue
- 24 / 11
Start / End Page
- 1497 - 1501
PubMed ID
- 31399500
Pubmed Central ID
- PMC6853096
Electronic International Standard Serial Number (EISSN)
- 1549-490X
Digital Object Identifier (DOI)
- 10.1634/theoncologist.2019-0316
Language
- eng
Conference Location
- England